A Study of Apalutamide Combined With GnRH Agonist in Participants With Androgen Receptor Positive Salivary Gland Carcinoma

Phase 2 Active not recruiting 31 enrolled Janssen Pharmaceutical K.K.

NaSingle-groupOpen-labelTreatment

Summary

The purpose of the study is to evaluate the overall response rate (ORR) of apalutamide in combination with a gonadotropin-releasing hormone (GnRH) agonist in participants with androgen receptor (AR) expressing locally advanced or recurrent/metastatic salivary gland carcinoma (SGC).

Timeline

Start: 2020-04-07
Primary completion: 2021-06-09
Completion: 2027-12-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Apalutamide	Small molecule	240 mg	Oral
Background	Goserelin	Other / unclassified	3.6 mg	—

A Study of Apalutamide Combined With GnRH Agonist in Participants With Androgen Receptor Positive Salivary Gland Carcinoma

Summary

Timeline

Drugs

Indications